Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SFX-01 after subarachnoid haemorrhage
2014-003284-38Phase 2Completed
- Sponsor
- TheraCryf
- Start
- Dec 2015
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of sulforadex in subarachnoid hemorrhage (SAH), sponsored by TheraCryf. Primary endpoint: Safety of SFX-01. Started Dec 2015; status: completed.
02
Drugs
sulforadex
03
Conditions
subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on 2014-003284-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003284-38.